Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program
BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and treatment institution, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of Curadev's small-molecule allosteric Stimulator of Interferon Genes (STING) agonist, CRD3874-SI, to be delivered systemically to patients with advanced/metastatic cancer.
The collaboration builds on the ongoing Phase 1a/b dose escalation and expansion clinical trial (NCT06021626) currently underway at MSK for sarcoma and Merkel cell carcinoma patients, and aims to explore the potential of CRD3874-SI in treating additional types of cancer. Through the MSK Therapeutics Accelerator program, MSK will provide Curadev with expertise and institutional resources, including medical, clinical, and regulatory advice, to further the development of CRD3874-SI. This expanded collaboration marks a significant milestone in translating promising STING pathway research into broader clinical application and will be overseen by William Tap, MD, Chief of the Sarcoma Medical Oncology Service at MSK, and Ciara Kelly, MBBCh BAO, Interim Clinical Director of MSK's Sarcoma Oncology Service.
Dr. William Tap said, "MSK and its Division of Solid Tumors are excited to co-develop CRD3874-SI, a novel first-in-class allosteric STING agonist, with Curadev. CRD3874-SI has demonstrated an encouraging safety and efficacy profile in a first-in-human study at MSK. CRD3874-SI is moving forward into multiple solid-tumor expansion cohorts, guided by disease specific experts and the support and structure of the MSK Accelerator Program, which is designed to enhance and expedite the development of novel compounds across malignancies. CRD3874-SI has the potential to offer patients a new treatment option with continued innovation and exploration of the benefits of immunotherapy in cancer care."
Dr. Arjun Surya, Co-founder and CEO of Curadev, added, "We are encouraged by the early readouts with CRD3874-SI systemic monotherapy from our ongoing clinical trial in patients with treatment refractory cancers at MSK and are honored by the opportunity to deepen our collaboration through the MSK Therapeutics Accelerator program. The research and development collaboration between oncologists at MSK and the inventors of CRD3874-SI at Curadev could become a role model for advancing bench to bedside medicines.
MSK's historic leadership position in the development of cancer immunotherapy and the exemplary dedication of the oncologists we work with is inspiring and make it an ideal partner in Curadev's effort to investigate the therapeutic potential of its systemically administered allosteric STING agonist in patients with advanced/metastatic cancer."
About Curadev
Curadev is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapeutics for treating intractable diseases. Curadev has built an impressive portfolio of discovery research programs using a target-centric approach, innovative screening schemes, and traditional wet-lab chemistry and pharmacology, resulting in patent-protected drug candidates that modulate next-generation drug targets. Curadev Pharma, Inc., the US-based clinical development subsidiary founded in 2021, is currently leading the Phase1/2 trials of STING agonist assets under a US FDA-approved IND application. For more information, visit www.curadev.in.
MSK's Therapeutics Accelerator program is a strategic partnership program between MSK and biotechnology companies to advance novel cancer therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK's community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on the treatment or management of cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Generation Mining Announces $10 Million Bought Deal Financing
TORONTO, June 11, 2025 /CNW/ - Generation Mining Ltd. (TSX: GENM) (OTCQB: GENMF) (" Generation Mining" or the " Company") announced today that it has entered into an agreement with Stifel Nicolaus Canada Inc. (" Stifel Canada") to act as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively, the " Underwriters") in connection with a "bought deal" private placement offering of 27,027,027 Units of the Company at a price of C$0.37 per Unit (the " Offering Price") for gross proceeds to the Company of up to C$10,000,000 (the " Offering"), with the Units to be issued pursuant to the Listed Issuer Financing Exemption (as defined below). Each Unit will consist of one common share in the capital of the Company and one-half of one common share purchase warrant (each whole warrant, a " Warrant"). Each Warrant will entitle the holder to purchase one common share of the Company at a price of C$0.48 per common share at any time on or before that date which is 36 months after the date that is 61 days following the closing date of the Offering. The Company has granted to the Underwriters an option, exercisable up to 48 hours prior to the closing date, to purchase for resale up to an additional 15% of Units at the Offering Price for additional gross proceeds of up to C$1,500,000. The Company intends to use the net proceeds received from the Offering for development purposes at the Company's Marathon Project and general corporate purposes. The Offering is expected to close on or about June 24, 2025 and is subject to the Company receiving all necessary regulatory approvals, including the conditional approval from the Toronto Stock Exchange. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions (" NI 45-106"), the Units will be offered for sale to purchasers resident in Canada, except Quebec, and/or other qualifying jurisdictions pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the " Listed Issuer Financing Exemption"). As the Offering is being completed pursuant to the Listed Issuer Financing Exemption, the Units issued pursuant to the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the Offering that can be accessed under the Company's issuer profile on SEDAR+ at and on the Company's website at Prospective investors should read the offering document before making an investment decision. No U.S. Offering or Registration This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. About the Company Generation Mining's focus is the development of the Marathon Project, a large undeveloped copper-palladium deposit in Northwestern Ontario. The Marathon Property covers a land package of approximately 26,000 hectares, or 260 square kilometers. Gen Mining is dedicated to fostering a greener future by promoting sustainability, empowering communities, and delivering value to our stakeholders. The Feasibility Study (the "Technical Report") estimated a Net Present Value (using a 6% discount rate) of C$1.07 billion, an Internal Rate of Return of 28%, and a 1.9-year payback based on the 3-yr trailing average metal prices at the effective date of the Technical Report. Over the anticipated 13-year mine life, the Marathon Project is expected to produce 2,161,000 ounces of palladium, 532 million lbs of copper, 488,000 ounces of platinum, 160,000 ounces of gold and 3,051,000 ounces of silver in payable metals. For more information, please review the Feasibility Study filed under the Company's profile at or on the Company's website at Qualified Person The scientific and technical content of this news release has been reviewed and approved by Daniel Janusauskas, Technical Services Manager of Generation PGM Inc., a wholly-owned subsidiary of the Company, and a Qualified Person as defined by Canadian Securities Administrators National Instrument 43-101 Standards of Disclosure for Mineral Projects. Forward-Looking Information This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to Offering, the proposed use of proceeds of the Offering, , receipt of all regulatory approvals related to the Offering, and the expected closing date of the Offering. Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include the timing of the Offering and regulatory approval of the Offering; timing for a construction decision; the progress of development at the Marathon Project, including progress of project expenditures and contracting processes, the Company's plans and expectations with respect to liquidity management, continued availability of capital and financing, the future prices of palladium, copper and other commodities, permitting timelines, exchange rates and currency fluctuations, increases in costs, requirements for additional capital, and the Company's decisions with respect to capital allocation, and the impact of COVID-19, inflation, global supply chain disruptions, global conflicts, including the wars in Ukraine and Israel, the project schedule for the Marathon Project, key inputs, staffing and contractors, continued availability of capital and financing, uncertainties involved in interpreting geological data and the accuracy of mineral reserve and resource estimates, environmental compliance and changes in environmental legislation and regulation, the Company's relationships with Indigenous communities, results from planned exploration and drilling activities, local access conditions for drilling, and general economic, market or business conditions, as well as those risk factors set out in the Company's annual information form for the year ended December 31, 2024, and in the continuous disclosure documents filed by the Company on SEDAR+ at
Cision Canada
an hour ago
- Cision Canada
Parkland Corporation Announces Second Quarter 2025 Dividend
CALGARY, AB, June 11, 2025 /CNW/ - Parkland Corporation ("Parkland") (TSX: PKI) announces that a dividend of $0.36 per share will be paid on July 15, 2025 to shareholders of record on June 20, 2025. The dividend will be an 'eligible dividend' for Canadian income tax purposes. About Parkland Corporation Parkland is a leading international fuel distributor, marketer, and convenience retailer with safe and reliable operations in 26 countries across the Americas. Our retail network meets the fuel and convenience needs of everyday consumers. Our commercial operations provide businesses with fuel to operate, complete projects and better serve their customers. In addition to meeting our customers' needs for essential fuels, Parkland provides a range of choices to help them lower their environmental impact, including manufacturing and blending renewable fuels, ultra-fast EV charging, a variety of solutions for carbon credits and renewables, and solar power. With approximately 4,000 retail and commercial locations across Canada, the United States and the Caribbean region, we have developed supply, distribution and trading capabilities to accelerate growth and business performance. Our strategy is focused on two interconnected pillars: our Customer Advantage and our Supply Advantage. Through our Customer Advantage, we aim to be the first choice of our customers through our proprietary brands, differentiated offers, extensive network, competitive pricing, reliable service, and compelling loyalty program. Our Supply Advantage is based on achieving the lowest cost to serve among independent fuel marketers and distributors in the hard-to-serve markets in which we operate, through our well-positioned assets, significant scale, and deep supply and logistics capabilities. Our business is underpinned by our people and our values of safety, integrity, community and respect, which are embedded across our organization.
Cision Canada
an hour ago
- Cision Canada
New Gold Announces Redemption of Remaining Outstanding 7.50% Senior Notes
(All amounts are in U.S. dollars unless otherwise indicated) TORONTO, June 11, 2025 /CNW/ - New Gold Inc. ("New Gold" or the "Company") (TSX: NGD) (NYSE American: NGD) announces that, pursuant to the terms of the indenture governing its 7.50% Senior Notes due 2027 (the "2027 Notes"), it has issued a notice of redemption to redeem the remaining $111 million aggregate principal amount of outstanding 2027 Notes on July 15, 2025. The redemption of the 2027 Notes will be funded with the remaining proceeds from the Company's March 2025 senior notes offering, together with cash on hand. About New Gold New Gold is a Canadian-focused intermediate mining Company with a portfolio of two core producing assets in Canada, the New Afton copper-gold mine and the Rainy River gold mine. New Gold's vision is to be the most valued intermediate gold and copper producer through profitable and responsible mining for our shareholders and stakeholders. For further information on the Company, visit Cautionary Note Regarding Forward-Looking Statements Certain information contained in this news release, including any information relating to New Gold's future financial or operating performance are "forward-looking" within the meaning of applicable Canadian and U.S. securities legislation. All statements, other than of historical fact, that address activities, events or developments that New Gold believes, expects or anticipates will or may occur in the future are forward-looking statements, including the redemption of the 2027 Notes and the funding thereof. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Although New Gold has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. New Gold does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. SOURCE New Gold Inc.
